Icon (NASDAQ:ICLR) Releases Earnings Results, Beats Estimates By $0.04 EPS

Icon (NASDAQ:ICLR) issued its quarterly earnings data on Tuesday. The medical research company reported $2.66 EPS for the quarter, topping the consensus estimate of $2.62 by $0.04, FiscalAI reports. The firm had revenue of $2.02 billion during the quarter, compared to the consensus estimate of $2.01 billion. During the same period in the previous year, the firm earned $3.31 EPS. The business’s revenue was down .9% on a year-over-year basis.

Icon Trading Up 11.8%

NASDAQ ICLR opened at $204.65 on Wednesday. Icon has a one year low of $66.57 and a one year high of $203.91. The stock has a 50 day moving average price of $169.42 and a 200-day moving average price of $146.06.

Insider Buying and Selling

In other Icon news, Director John Climax sold 5,005 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $175.00, for a total transaction of $875,875.00. Following the sale, the director directly owned 2,087 shares of the company’s stock, valued at $365,225. The trade was a 70.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Ciaran Murray sold 2,677 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $164.29, for a total value of $439,804.33. Following the completion of the sale, the director directly owned 20,452 shares of the company’s stock, valued at $3,360,059.08. The trade was a 11.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 23,068 shares of company stock valued at $3,936,744 in the last quarter. 44.00% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d)” rating on shares of Icon in a research report on Wednesday, August 26th. Robert W. Baird set a $194.00 target price on shares of Icon in a research report on Friday, July 31st. UBS Group initiated coverage on shares of Icon in a research note on Wednesday, September 30th. They set a “neutral” rating and a $195.00 target price for the company. Citigroup reduced their price target on shares of Icon from $180.00 to $175.00 and set a “neutral” rating on the stock in a report on Friday, September 18th. Finally, Bank of America upgraded shares of Icon from an “underperform” rating to a “neutral” rating and set a $185.00 price target on the stock in a research note on Friday, October 9th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $174.73.

Key Icon News

Here are the key news stories impacting Icon this week:

• Positive Sentiment: Quarterly results exceeded expectations. ICON reported non-GAAP earnings of $2.66 per share versus the $2.62–$2.64 consensus range, while revenue of approximately $2.02 billion topped estimates near $2.01 billion. ICON Q3 Earnings and Revenues Beat Estimates
• Positive Sentiment: Management raised 2026 guidance. The improved outlook supports the view that ICON’s clinical research business is stabilizing, while its reported backlog of roughly $24.5 billion provides longer-term revenue visibility. ICON Q3 Earnings and Guidance
• Positive Sentiment: Share repurchases support per-share value. ICON redeemed approximately 2.36 million shares during the third quarter, which can improve future EPS and signals continued capital returns. ICON Note Issuance and Share Redemption
• Neutral Sentiment: Financing strengthens liquidity but increases debt exposure. The $2.15 billion note issuance provides capital for corporate needs and shareholder returns, but investors may weigh higher interest obligations and leverage against the buyback benefit.
• Neutral Sentiment: Insider selling appears administrative. Chief Accounting Officer Emer Lyons sold 272 shares worth about $49,600 to cover tax withholding tied to vested equity awards, reducing the likelihood that the transaction reflects a negative view of ICLR’s prospects. ICON Insider Sale
• Negative Sentiment: Underlying year-over-year comparisons remain weak. Quarterly EPS fell from $3.31 to $2.66, and revenue declined 0.9%, suggesting that the headline beats were modest and that operating recovery is not yet fully established. ICON Third-Quarter Results

Icon Company Profile

ICON plc is a global contract research organization that provides outsourced development services to pharmaceutical, biotechnology and medical device companies. The company supports clinical research programs from early development through late-stage trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, medical and regulatory consulting, biostatistics, data management, pharmacovigilance, laboratory services and real-world evidence solutions.